MicroRNA-148b-3p and MicroRNA-25-3p Are Overexpressed in Fetuses with Late-Onset Fetal Growth Restriction
Por:
Morales-Roselló J, García-Giménez JL, Martinez L, González-Rodríguez D, Mena-Mollá S, Maquieira Catalá A, Loscalzo G, Buongiorno S, Jakaite V, Cañada Martínez AJ and Perales Marín A
Publicada:
1 sep 2020
Ahead of Print:
25 jun 2020
Resumen:
Objective:It was the aim of this study to describe a micro-RNA (miRNA) profile characteristic of late-onset fetal growth restriction (FGR) and to investigate the pathways involved in their biochemical action.Methods:In this prospective study, 25 fetuses (16 normal and 9 with FGR [estimated fetal weight <10th centile plus cerebroplacental ratio <0.6765 multiples of the median]) were evaluated with Doppler ultrasound after 36 weeks. Afterwards, for every fetus, plasma from umbilical vein blood was collected at birth, miRNA was extracted, and full miRNA sequencing was performed. Subsequently, comparisons were done in order to obtain those miRNAs that were differentially expressed.Results:The FGR fetuses expressed upregulation of two miRNAs: miR-25-3p and, especially, miR-148b-3p, a miRNA directly involved in Schwann cell migration, neuronal plasticity, and energy metabolism (p= 0.0072,p= 0.0013).Conclusions:FGR fetuses express a different miRNA profile, which includes overexpression of miR-25-3p and miR-148b-3p. This information might improve our understanding of the pathophysiological processes involved in late-onset FGR. Future validation and feasibility studies will be required to propose miRNAs as a valid tool in the diagnosis and management of FGR.
Filiaciones:
Morales-Roselló J:
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain,
Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain,
García-Giménez JL:
EpiDisease SL, and Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
Departamento de Fisiología, Universidad de Valencia, Valencia, Spain
Martinez L:
Servicio de Secuenciación, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad valenciana (FISABIO), Valencia, Spain
González-Rodríguez D:
EpiDisease SL, and Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
Mena-Mollá S:
EpiDisease SL, and Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain
Departamento de Fisiología, Universidad de Valencia, Valencia, Spain
Maquieira Catalá A:
Departamento de Química, Universidad Politécnica de Valencia, Valencia, Spain
Loscalzo G:
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Buongiorno S:
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Jakaite V:
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Cañada Martínez AJ:
Unidad de Bioestadística, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
Perales Marín A:
Servicio de Obstetricia, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Departamento de Pediatría, Obstetricia y Ginecología, Universidad de Valencia, Valencia, Spain
Green Submitted
|